PEGylated Artificial Antibodies: Plasmonic Biosensors with Improved Selectivity.

Luan J, Liu KK, Tadepalli S, Jiang Q, Morrissey JJ, Kharasch ED, Singamaneni S (2016) PEGylated Artificial Antibodies: Plasmonic Biosensors with Improved Selectivity. ACS applied materials & interfaces, 8(36):23509-16.

 PubMed


Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease.

Horst J, Frei-Jones M, Deych E, Shannon W, Kharasch ED (2016) Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease. Pediatric blood & cancer, ():.

 PubMed


Silk-Encapsulated Plasmonic Biochips with Enhanced Thermal Stability.

Wang C, Luan J, Tadepalli S, Liu KK, Morrissey JJ, Kharasch ED, Naik RR, Singamaneni S (2016) Silk-Encapsulated Plasmonic Biochips with Enhanced Thermal Stability. ACS applied materials & interfaces, ():.

 PubMed


Development, validation and application of a comprehensive stereoselective LC/MS-MS assay for bupropion and oxidative, reductive, and glucuronide metabolites in human urine.

Teitelbaum AM, Flaker AM, Kharasch ED (2016) Development, validation and application of a comprehensive stereoselective LC/MS-MS assay for bupropion and oxidative, reductive, and glucuronide metabolites in human urine. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1027():239-53.

 PubMed


Changes: Thank You, Dr. Eisenach.

Kharasch ED, Tedeschi V, Kendall G (2016) Changes: Thank You, Dr. Eisenach. Anesthesiology, 125(1):1-3.

 PubMed


Changes: Handing Off and the Future of ANESTHESIOLOGY.

Kharasch ED (2016) Changes: Handing Off and the Future of ANESTHESIOLOGY. Anesthesiology, 125(1):4-6.

 PubMed


Fentanyl and Midazolam Are Ineffective in Reducing Episodic Intracranial Hypertension in Severe Pediatric Traumatic Brain Injury.

Welch TP, Wallendorf MJ, Kharasch ED, Leonard JR, Doctor A, Pineda JA (2016) Fentanyl and Midazolam Are Ineffective in Reducing Episodic Intracranial Hypertension in Severe Pediatric Traumatic Brain Injury. Critical care medicine, 44(4):809-18.

 PubMed


Perioperative Opioids and Public Health.

Kharasch ED, Brunt LM (2016) Perioperative Opioids and Public Health. Anesthesiology, 124(4):960-5.

 PubMed


Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma.

Teitelbaum AM, Flaker AM, Kharasch ED (2016) Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1017-1018():101-13.

 PubMed


Wherefore Gabapentinoids?: Was There Rush Too Soon to Judgment?

Kharasch ED, Eisenach JC (2016) Wherefore Gabapentinoids?: Was There Rush Too Soon to Judgment? Anesthesiology, 124(1):10-2.

 PubMed


Effect of HAART on Brain Organization and Function in HIV-Negative Subjects.

Brier MR, Wu Q, Tanenbaum AB, Westerhaus ET, Kharasch ED, Ances BM (2015) Effect of HAART on Brain Organization and Function in HIV-Negative Subjects. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 10(4):517-21.

 PubMed


Peptide Functionalized Gold Nanorods for the Sensitive Detection of a Cardiac Biomarker Using Plasmonic Paper Devices.

Tadepalli S, Kuang Z, Jiang Q, Liu KK, Fisher MA, Morrissey JJ, Kharasch ED, Slocik JM, Naik RR, Singamaneni S (2015) Peptide Functionalized Gold Nanorods for the Sensitive Detection of a Cardiac Biomarker Using Plasmonic Paper Devices. Scientific reports, 5():16206.

 PubMed


Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.

Kharasch ED, Regina KJ, Blood J, Friedel C (2015) Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. Anesthesiology, 123(5):1142-53.

 PubMed


Bio-Enabled Gold Superstructures with Built-In and Accessible Electromagnetic Hotspots.

Tian L, Fei M, Tadepalli S, Morrissey JJ, Kharasch ED, Singamaneni S (2015) Bio-Enabled Gold Superstructures with Built-In and Accessible Electromagnetic Hotspots. Advanced healthcare materials, 4(10):1502-9, 1423.

 PubMed


Differences in Methadone Metabolism by CYP2B6 Variants.

Gadel S, Friedel C, Kharasch ED (2015) Differences in Methadone Metabolism by CYP2B6 Variants. Drug metabolism and disposition: the biological fate of chemicals, 43(7):994-1001.

 PubMed


The hematological effects of nitrous oxide anesthesia in pediatric patients.

Duma A, Cartmill C, Blood J, Sharma A, Kharasch ED, Nagele P (2015) The hematological effects of nitrous oxide anesthesia in pediatric patients. Anesthesia and analgesia, 120(6):1325-30.

 PubMed


Influence of HIV antiretrovirals on methadone N-demethylation and transport.

Campbell SD, Gadel S, Friedel C, Crafford A, Regina KJ, Kharasch ED (2015) Influence of HIV antiretrovirals on methadone N-demethylation and transport. Biochemical pharmacology, 95(2):115-25.

 PubMed


Opioid Half-lives and Hemlines: The Long and Short of Fashion.

Kharasch ED, {Authors/Author/Name#2} (2015) Opioid Half-lives and Hemlines: The Long and Short of Fashion. Anesthesiology, 122(5):969-70.

 PubMed


Steroid Anesthesia Revisited: Again.

Kharasch ED, Hollmann MW (2015) Steroid Anesthesia Revisited: Again. Anesthesia and analgesia, 120(5):983-4.

 PubMed


Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study.

Morrissey JJ, Mellnick VM, Luo J, Siegel MJ, Figenshau RS, Bhayani S, Kharasch ED (2015) Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study. JAMA oncology, 1(2):204-12.

 PubMed


Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer.

Morrissey JJ, Mobley J, Figenshau RS, Vetter J, Bhayani S, Kharasch ED (2015) Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer. Mayo Clinic proceedings, 90(1):35-42.

 PubMed


Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics.

Kharasch E.D., Whittington D., Ensign D., Hoffer C., Bedynek P.S., Campbell S., Stubbert K., Crafford A., London A., Kim T. (2012) Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clinical pharmacology and therapeutics, 91(4):673-84.

 PubMed


Getting oil and water to mix.

Kharasch E.D. (2012) Getting oil and water to mix. Anesthesiology, 116(3):504-6.

 PubMed


Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion.

Kirby B.J., Collier A.C., Kharasch E.D., Whittington D., Thummel K.E., Unadkat J.D. (2012) Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug metabolism and disposition: the biological fate of chemicals, 40(3):610-6.

 PubMed


Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).

Kharasch E.D., Bedynek P.S., Hoffer C., Walker A., Whittington D. (2012) Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology, 116(2):432-47.

 PubMed


Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.

Crews K.R., Gaedigk A., Dunnenberger H.M., Klein T.E., Shen D.D., Callaghan J.T., Kharasch E.D., Skaar T.C. (2012) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clinical pharmacology and therapeutics, 91(2):321-6.

 PubMed


Perioperative pharmacokinetics of methadone in adolescents.

Sharma A., Tallchief D., Blood J., Kim T., London A., Kharasch E.D. (2011) Perioperative pharmacokinetics of methadone in adolescents. Anesthesiology, 115(6):1153-61.

 PubMed


Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

Brown S.M., Holtzman M., Kim T., Kharasch E.D. (2011) Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology, 115(6):1251-60.

 PubMed


Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.

Kirby B.J., Collier A.C., Kharasch E.D., Dixit V., Desai P., Whittington D., Thummel K.E., Unadkat J.D. (2011) Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug metabolism and disposition: the biological fate of chemicals, 39(12):2329-37.

 PubMed


Nitrous oxide anesthesia and plasma homocysteine in adolescents.

Nagele P., Tallchief D., Blood J., Sharma A., Kharasch E.D. (2011) Nitrous oxide anesthesia and plasma homocysteine in adolescents. Anesthesia and analgesia, 113(4):843-8.

 PubMed


Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection.

Toma O., Suntrup P., Stefanescu A., London A., Mutch M., Kharasch E. (2011) Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection. Anesthesia and analgesia, 113(4):730-7.

 PubMed


The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.

Bloom J., Hinrichs A.L., Wang J.C., Von Weymarn L.B., Kharasch E.D., Bierut L.J., Goate A., Murphy S.E. (2011) The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenetics and genomics, 21(7):403-16.

 PubMed


Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.

Kharasch E.D., Francis A., London A., Frey K., Kim T., Blood J. (2011) Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction. Clinical pharmacology and therapeutics, 90(1):100-8.

 PubMed


Headache outcomes following treatment of unruptured intracranial aneurysms: a prospective analysis.

Schwedt T.J., Gereau R.W., Frey K., Kharasch E.D. (2011) Headache outcomes following treatment of unruptured intracranial aneurysms: a prospective analysis. Cephalalgia : an international journal of headache, 31(10):1082-9.

 PubMed


Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration.

Noppers I., Olofsen E., Niesters M., Aarts L., Mooren R., Dahan A., Kharasch E., Sarton E. (2011) Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration. Anesthesiology, 114(6):1435-45.

 PubMed


Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.

Kirby B.J., Collier A.C., Kharasch E.D., Whittington D., Thummel K.E., Unadkat J.D. (2011) Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug metabolism and disposition: the biological fate of chemicals, 39(6):1070-8.

 PubMed


Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry.

Kim T., London A., Kharasch E.D. (2011) Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis, 55(3):487-93.

 PubMed


Chemical and enzyme-assisted syntheses of norbuprenorphine-3-β-D-glucuronide.

Fan J., Brown S.M., Tu Z., Kharasch E.D. (2011) Chemical and enzyme-assisted syntheses of norbuprenorphine-3-β-D-glucuronide. Bioconjugate chemistry, 22(4):752-8.

 PubMed


Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.

Kharasch E.D., Vangveravong S., Buck N., London A., Kim T., Blood J., MacH R.H. (2011) Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil. Clinical pharmacology and therapeutics, 89(4):562-70.

 PubMed


Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma.

Morrissey J.J., London A.N., Lambert M.C., Kharasch E.D. (2011) Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma. American journal of nephrology, 34(5):391-8.

 PubMed


Intraoperative methadone: rediscovery, reappraisal, and reinvigoration?

Kharasch E.D. (2011) Intraoperative methadone: rediscovery, reappraisal, and reinvigoration? Anesthesia and analgesia, 112(1):13-6.

 PubMed


Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.

Joy M.S., Frye R.F., Stubbert K., Brouwer K.R., Falk R.J., Kharasch E.D. (2010) Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. Journal of clinical pharmacology, 50(6):714-20.

 PubMed


Urinary biomarkers for the early diagnosis of kidney cancer.

Morrissey J.J., London A.N., Luo J., Kharasch E.D. (2010) Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clinic proceedings. Mayo Clinic, 85(5):413-21.

 PubMed


Pressure waveform monitoring during central venous catheterization.

Bowdle A., Kharasch E., Schwid H. (2009) Pressure waveform monitoring during central venous catheterization. Anesthesia and analgesia, 109(6):2030-1; author reply 2031.

 PubMed


Blast-related brain injury: imaging for clinical and research applications: report of the 2008 st. Louis workshop.

Benzinger T.L.S., Brody D., Cardin S., Curley K.C., Mintun M.A., Mun S.K., Wong K.H., Wrathall J.R., Armstrong R.C., Bayly P.V., Bentley T.B., Chavko M., Corbetta M., Culver J.P., DeWitt D.S., Faden A.I., Fiskum G., Fitzpatrick S.M., Gennarelli T., Ghajar J., Gullapalli R.P., Hovda D., Jost R.G., Kharasch E.D., Kharasch K., Kochanek P., Lammle M., Leggieri Jr. M.J., Latour L.L., Little D.M., Mac Donald C.L., Macedonia C., Marcus D., McCabe J.T., McCarron R.M., Moore D., Mukherjee P., Povlishock J., Pancrazio J., Petersen S., Peskind E.R., Pierce K.J., Pineda J.A., Raskind M., Riedel C., Ritzel D., Shimony J.S., Smith A.B., Smith D.H., Smirniotopoulos J., Song V.S.-K., Sterkel B.B., Svetlov S., VandeVord P.J., Young A.W., Zipfel G. (2009) Blast-related brain injury: imaging for clinical and research applications: report of the 2008 st. Louis workshop. Journal of neurotrauma, 26(12):2127-44.

 PubMed


Expanded studies of the pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers.

Pickrell J.E., Hosaka K., Jackson D.L., Heima M., Kharasch E., Milgrom P.M. (2009) Expanded studies of the pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers. Journal of clinical psychopharmacology, 29(5):426-31.

 PubMed


The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine.

Montana M.C., Cavallone L.F., Stubbert K.K., Stefanescu A.D., Kharasch E.D., Gereau IV R.W. (2009) The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine. The Journal of pharmacology and experimental therapeutics, 330(3):834-43.

 PubMed


Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.

Kharasch E.D., Walker A., Whittington D., Hoffer C., Bedynek P.S. (2009) Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug and alcohol dependence, 101(3):158-68.

 PubMed


Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.

Kharasch E.D., Hoffer C., Whittington D., Walker A., Bedynek P.S. (2009) Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology, 110(3):660-72.

 PubMed


Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.

Kharasch E.D., Bedynek P.S., Walker A., Whittington D., Hoffer C. (2008) Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clinical pharmacology and therapeutics, 84(4):506-12.

 PubMed


Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.

Kharasch E.D., Bedynek P.S., Park S., Whittington D., Walker A., Hoffer C. (2008) Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clinical pharmacology and therapeutics, 84(4):497-505.

 PubMed


Mutations in a molecule: the virtues of antagonism.

Kharasch E.D. (2008) Mutations in a molecule: the virtues of antagonism. Mayo Clinic proceedings. Mayo Clinic, 83(10):1083-6.

 PubMed


Journal-related and other special activities at the 2008 American Society of Anesthesiologists Annual Meeting.

Lerman J., Kharasch E.D., Eisenach J.C., Warner M.A., Jevtovic-Todorovic V., Patel P.M., Sun L.S. (2008) Journal-related and other special activities at the 2008 American Society of Anesthesiologists Annual Meeting. Anesthesiology, 109(3):365.

 PubMed


Adverse drug reactions with halogenated anesthetics.

Kharasch E.D. (2008) Adverse drug reactions with halogenated anesthetics. Clinical pharmacology and therapeutics, 84(1):158-62.

 PubMed


Molecular characterization of CYP2B6 substrates.

Ekins S., Iyer M., Krasowski M.D., Kharasch E.D. (2008) Molecular characterization of CYP2B6 substrates. Current drug metabolism, 9(5):363-73.

 PubMed


Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.

Coles R., Kharasch E.D. (2008) Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes. Pharmaceutical research, 25(6):1405-11.

 PubMed


Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.

Kharasch E.D., Mitchell D., Coles R., Blanco R. (2008) Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrobial agents and chemotherapy, 52(5):1663-9.

 PubMed


Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.

Kharasch E.D., Mitchell D., Coles R. (2008) Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. Journal of clinical pharmacology, 48(4):464-74.

 PubMed


Role of CYP2B6 in stereoselective human methadone metabolism.

Totah R.A., Sheffels P., Roberts T., Whittington D., Thummel K., Kharasch E.D. (2008) Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology, 108(3):363-74.

 PubMed


Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.

Templeton I.E., Thummel K.E., Kharasch E.D., Kunze K.L., Hoffer C., Nelson W.L., Isoherranen N. (2008) Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clinical pharmacology and therapeutics, 83(1):77-85.

 PubMed


Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.

Kharasch E.D., Walker A., Isoherranen N., Hoffer C., Sheffels P., Thummel K., Whittington D., Ensign D. (2007) Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clinical pharmacology and therapeutics, 82(4):410-26.

 PubMed


Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS.

Coles R., Kharasch E.D. (2007) Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 857(1):67-75.

 PubMed


Every breath you take, we'll be watching you.

Kharasch E.D., Shelden R.D., Shelden M.B. (2007) Every breath you take, we'll be watching you. Anesthesiology, 106(4):652-4.

 PubMed


Enantiomeric metabolic interactions and stereoselective human methadone metabolism.

Totah R.A., Allen K.E., Sheffels P., Whittington D., Kharasch E.D. (2007) Enantiomeric metabolic interactions and stereoselective human methadone metabolism. The Journal of pharmacology and experimental therapeutics, 321(1):389-99.

 PubMed


Pharmacokinetic interactions between buprenorphine and antiretroviral medications.

Bruce R.D., McCance-Katz E., Kharasch E.D., Moody D.E., Morse G.D. (2006) Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 43 Suppl 4():S216-23.

 PubMed


Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities.

Kirby B., Kharasch E.D., Thummel K.T., Narang V.S., Hoffer C.J., Unadkat J.D. (2006) Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities. Journal of clinical pharmacology, 46(11):1313-9.

 PubMed


New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development (part 2): Identification of nephrotoxic metabolites.

Kharasch E.D., Schroeder J.L., Liggitt H.D., Ensign D., Whittington D. (2006) New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development (part 2): Identification of nephrotoxic metabolites. Anesthesiology, 105(4):737-45.

 PubMed


New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development (part 1): Identification of the nephrotoxic metabolic pathway.

Kharasch E.D., Schroeder J.L., Liggitt H.D., Park S.B., Whittington D., Sheffels P. (2006) New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development (part 1): Identification of the nephrotoxic metabolic pathway. Anesthesiology, 105(4):726-36.

 PubMed


Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.

Lalovic B., Kharasch E., Hoffer C., Risler L., Liu-Chen L.-Y., Shen D.D. (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clinical pharmacology and therapeutics, 79(5):461-79.

 PubMed


Stereochemical aspects of itraconazole metabolism in vitro and in vivo.

Kunze K.L., Nelson W.L., Kharasch E.D., Thummel K.E., Isoherranen N. (2006) Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug metabolism and disposition: the biological fate of chemicals, 34(4):583-90.

 PubMed


Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("compound A") in rats.

Kharasch E.D., Schroeder J.L., Bammler T., Beyer R., Srinouanprachanh S. (2006) Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("compound A") in rats. Toxicological sciences : an official journal of the Society of Toxicology, 90(2):419-31.

 PubMed


Pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers.

Jackson D.L., Milgrom P., Heacox G.A., Kharasch E.D. (2006) Pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers. Journal of clinical psychopharmacology, 26(1):4-8.

 PubMed


Influence of sevoflurane on the metabolism and renal effects of compound A in rats.

Kharasch E.D., Schroeder J.L., Sheffels P., Liggitt H.D. (2005) Influence of sevoflurane on the metabolism and renal effects of compound A in rats. Anesthesiology, 103(6):1183-8.

 PubMed


Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.

Chaobal H.N., Kharasch E.D. (2005) Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clinical pharmacology and therapeutics, 78(5):529-39.

 PubMed


Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.

Kharasch E.D., Walker A., Hoffer C., Sheffels P. (2005) Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. Journal of clinical pharmacology, 45(10):1187-97.

 PubMed


CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition.

Kharasch E.D., Thummel K.E., Watkins P.B. (2005) CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition. Molecular interventions, 5(3):151-3.

 PubMed


Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5.

Klees T.M., Sheffels P., Thummel K.E., Kharasch E.D. (2005) Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology, 102(3):550-6.

 PubMed


Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.

Klees T.M., Sheffels P., Dale O., Kharasch E.D. (2005) Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. Drug metabolism and disposition: the biological fate of chemicals, 33(3):303-11.

 PubMed


Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans.

Dembo G., Park S.B., Kharasch E.D. (2005) Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology, 102(2):409-15.

 PubMed


Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.

Kharasch E.D., Whittington D., Hoffer C., Krudys K., Craig K., Vicini P., Sheffels P., Lalovic B. (2005) Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies. Clinical pharmacokinetics, 44(7):731-51.

 PubMed


Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.

Kharasch E.D., Walker A., Hoffer C., Sheffels P. (2005) Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. Journal of clinical pharmacology, 45(1):79-88.

 PubMed


Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.

Kharasch E.D., Walker A., Hoffer C., Sheffels P. (2004) Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clinical pharmacology and therapeutics, 76(5):452-66.

 PubMed


In vitro metabolism of cyclosporine A by human kidney CYP3A5.

Dai Y., Iwanaga K., Lin Y.S., Hebert M.F., Davis C.L., Huang W., Kharasch E.D., Thummel K.E. (2004) In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochemical pharmacology, 68(9):1889-902.

 PubMed


Stereoselective determination of methadone and the primary metabolite EDDP in human plasma by automated on-line extraction and liquid chromatography mass spectrometry.

Whittington D., Sheffels P., Kharasch E.D. (2004) Stereoselective determination of methadone and the primary metabolite EDDP in human plasma by automated on-line extraction and liquid chromatography mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 809(2):313-21.

 PubMed


Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats.

Sheffels P., Schroeder J.L., Altuntas T.G., Liggitt H.D., Kharasch E.D. (2004) Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats. Chemical research in toxicology, 17(9):1177-89.

 PubMed


Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.

Kharasch E.D., Hoffer C., Whittington D., Sheffels P. (2004) Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clinical pharmacology and therapeutics, 76(3):250-69.

 PubMed


Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate.

Kharasch E.D., Hoffer C., Whittington D. (2004) Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate. Anesthesiology, 101(3):738-43.

 PubMed


Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate.

Kharasch E.D., Whittington D., Hoffer C. (2004) Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. Anesthesiology, 101(3):729-37.

 PubMed


Bioavailabilities of rectal and oral methadone in healthy subjects.

Dale O., Sheffels P., Kharasch E.D. (2004) Bioavailabilities of rectal and oral methadone in healthy subjects. British journal of clinical pharmacology, 58(2):156-62.

 PubMed


The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

Kharasch E.D., Hoffer C., Whittington D. (2004) The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. British journal of clinical pharmacology, 57(5):600-10.

 PubMed


Sulfoxidation of cysteine and mercapturic acid conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A).

Altuntas T.G., Park S.B., Kharasch E.D. (2004) Sulfoxidation of cysteine and mercapturic acid conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A). Chemical research in toxicology, 17(3):435-45.

 PubMed


Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl.

Kharasch E.D., Hoffer C., Altuntas T.G., Whittington D. (2004) Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. Journal of clinical pharmacology, 44(3):224-33.

 PubMed


Perioperative COX-2 inhibitors: knowledge and challenges.

Kharasch E.D. (2004) Perioperative COX-2 inhibitors: knowledge and challenges. Anesthesia and analgesia, 98(1):1-3.

 PubMed


Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.

Kharasch E.D., Hoffer C., Whittington D., Sheffels P. (2003) Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clinical pharmacology and therapeutics, 74(6):543-54.

 PubMed


Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients.

Fitzgibbon D., Morgan D., Dockter D., Barry C., Kharasch E.D. (2003) Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain, 106(3):309-15.

 PubMed


Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line.

Altuntas T.G., Zager R.A., Kharasch E.D. (2003) Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line. Toxicology and applied pharmacology, 193(1):55-65.

 PubMed


Determination of morphine and morphine glucuronides in human plasma by 96-well plate solid-phase extraction and liquid chromatography-electrospray ionization mass spectrometry.

Whittington D., Kharasch E.D. (2003) Determination of morphine and morphine glucuronides in human plasma by 96-well plate solid-phase extraction and liquid chromatography-electrospray ionization mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 796(1):95-103.

 PubMed


Safety of low-flow sevoflurane anesthesia in patients with chronically impaired renal function is not proven.

Saidman L.J., Eger E.I., Kharasch E.D., Conzen P., Michalowski P., Weiss B.M., Rooke G.A., Artru A., Ebert T., Czerner S.F.A., Reichle F.M. (2003) Safety of low-flow sevoflurane anesthesia in patients with chronically impaired renal function is not proven. Anesthesiology, 99(3):752; author reply 752-4.

 PubMed


CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease.

Emery M.G., Fisher J.M., Chien J.Y., Kharasch E.D., Dellinger E.P., Kowdley K.V., Thummel K.E. (2003) CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.), 38(2):428-35.

 PubMed


Concordance between trifluoroacetic acid and hepatic protein trifluoroacetylation after disulfiram inhibition of halothane metabolism in rats.

Spracklin D.K., Emery M.E., Thummel K.E., Kharasch E.D. (2003) Concordance between trifluoroacetic acid and hepatic protein trifluoroacetylation after disulfiram inhibition of halothane metabolism in rats. Acta anaesthesiologica Scandinavica, 47(6):765-70.

 PubMed